Logo
Home
Company ProfileBoards & StaffsMemberships & PartnersAcademy of JournalismCareersBlog(EN)Contact Us
Our JournalsInstruction for AuthorsBrieflands PoliciesPublish My ResearchJournal Management SystemArticle Processing ChargesOpen Peer ReviewPublishing Services
Publish My Book
  1. Brieflands
  2. journals
  3. Jundishapur Journal of Microbiology
  4. Articles

  5. Molecular Epidemiology of Hepatitis C Virus Genotypes Among Chronically Infected Patients in Pakistan
  6. Crossref

Jundishapur Journal of Microbiology

Ahvaz Jundishapur University of Medical Sciences

Home
Current IssueAll IssuesIn PressAccepted ManuscriptsSearch
Instructions
Journal InformationEditors & BoardsIndexing and Listing SourcesJournal MetricsOpen Peer Review (OPR)Publication Ethics and Malpractice StatementReviewer and AE Registration FormSupportContact Us
APC
Authors GuideSubmit Manuscript

Crossref


1. Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals

- Saima Mushtaq

- Asraf Hussain Hashmi

- Amjad Khan

- Syed Muhammad Asad Raza Kazmi

- Sobia Manzoor

2. Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan

- Saima Mushtaq

- Tayyab Saeed Akhter

- Amjad Khan

- Aamir Sohail

- Arshad Khan

- Sobia Manzoor

3. Efficacy of Sofosbuvir and Velpatasvir Combination in the Treatment of Hepatitis C Virus (HCV) in Chronic Kidney Disease (CKD) Patients

- Noor Mohammad

- Dilaram Khan

HomeInstructionsAPC

Articles

  • Current Issue
  • All Issues
  • In Press
  • Accepted Manuscripts
  • Search

About Journal

  • Journal Information
  • Editors & Boards
  • Indexing and Listing Sources
  • Journal Metrics
  • Open Peer Review (OPR)
  • Publication Ethics and Malpractice Statement
  • Reviewer and AE Registration Form
  • Support
  • Contact Us
Support
Submit a Ticket
BrieflandsBrieflands

Science, Technical, Medical Publisher, Since 2007

All rights reserved by Brieflands, 2026.

Powered by Neoscriber.